Zou Di, Jawaid Imran, Amoaku Winfried M
Queen's Medical Centre, Derby Road, Nottingham NG72UH, UK.
Division of Clinical Neurosciences, Academic Ophthalmology, University of Nottingham, Nottingham University Hospitals NHS Trust, Nottingham, UK.
J Ophthalmol. 2021 Jul 27;2021:9967831. doi: 10.1155/2021/9967831. eCollection 2021.
We performed a retrospective review of outcomes in 81 pseudophakic eyes with DMO that received at least 6 anti-VEGF injections. We reviewed baseline and posttreatment optical coherence tomography images, visual acuity, prescribing patterns, time taken to deliver anti-VEGF injections, and structural and functional outcomes.
It took an average of 913 ± 454.1 days to deliver a mean of 11.1 ± 4.7 anti-VEGF injections. Time from baseline to receiving the first 6 anti-VEGF injections was longer than 9 months in 74.7% ( = 59/79) of eyes. There was a mean gain of 1.6 letters (-0.03 logMAR) from baseline to the end point. After 5 anti-VEGF intravitreal injections, the mean CMT was 391.9 m from 474.4 m at baseline ( < 0.0001). In 52 of 79 eyes (65.8%), more than one type of anti-VEGF agent was used.
The anti-VEGF treatment used to treat these eyes with DMO was suboptimal, a finding consistent with recently published "real-world" data. There was a strong tendency for patients to be switched within the class to a second anti-VEGF agent.
我们对81只患有糖尿病性黄斑水肿（DMO）且接受了至少6次抗血管内皮生长因子（anti-VEGF）注射的人工晶状体眼的治疗结果进行了回顾性分析。我们查看了基线期和治疗后的光学相干断层扫描图像、视力、用药模式、进行抗VEGF注射所需的时间，以及结构和功能方面的结果。
平均进行了11.1±4.7次抗VEGF注射，平均用时913±454.1天。74.7%（n = 59/79）的患眼从基线期到接受前6次抗VEGF注射的时间超过9个月。从基线期到终点，平均视力提高了1.6个字母（-0.03 logMAR）。在进行5次抗VEGF玻璃体内注射后，平均中心凹视网膜厚度（CMT）从基线期的474.4μm降至391.9μm（P<0.0001）。79只眼中有52只（65.8%）使用了不止一种类型的抗VEGF药物。
用于治疗这些患有DMO患眼的抗VEGF治疗并不理想，这一结果与最近发表的“真实世界”数据一致。患者很有可能在同一类药物中换用第二种抗VEGF药物。
